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ABSTRACT
Asthma is one of the most common chronic medical condi-
tions that may complicate pregnancy. Asthma influences the
outcome of pregnancy and, vice versa, pregnancy affects
asthma severity, but the underlying immunological mecha-
nisms of this interaction are not fully understood. As a sign of
pregnancy-induced immunotolerance, attenuation of allergic
responses can be detected in controlled asthmatic pregnant
patients; however non controlled asthmatic pregnant women
show significant asthma-associated immune reactions that
may, beside other factors, influence fetal growth. Generally,
although uncontrolled asthma may increase the risk of
adverse perinatal outcomes, women with well-controlled and
adequately treated disease during pregnancy do not develop
maternal or fetal complications. 
Keywords: Asthma, clinical management, immunological inter-
actions, inflammation, pregnancy.
RIASSUNTO 
L’asma è una delle patologie croniche più comuni che possono
complicare la gravidanza. L’asma influenza il decorso della
gravidanza e, a sua volta, la gravidanza influenza la gravità
dell’asma; tuttavia il substrato immunologico che sottende a
questa interazione non è ancora completamente delucidato. A
riprova dell’immunotolleranza indotta dalla gravidanza si può
rilevare un’attenuazione della reazione allergica riscontrabile
nelle pazienti gravide con asma controllato; al contrario pa-
zienti gravide con asma non controllato mostrano importanti
reazioni immuni associate all’asma che, oltre tutto, influenza-
no la crescita fetale. In generale, sebbene un asma non con-
trollato possa aumentare il rischio di eventi avversi perinatali,
le donne con asma ben controllato e che hanno ricevuto un
trattamento adeguato durante la gravidanza non sviluppano
complicanze materne o fetali.
Parole chiave: Asma, gestione clinica, gravidanza, infiamma-
zione, interazioni immunologiche. 
INTRODUCTION
Asthma is one of the most common chronic medical
conditions that may complicate pregnancy, with a
prevalence of 3.7 - 8.4% of all pregnancies [1].
Pregnant women with asthma represent a special
challenge for asthma specialists and allergists.
Asthma influences the outcome of pregnancy and,
vice versa, pregnancy affects asthma severity, but the
underlying immunological mechanisms of this inter-
action are not fully understood. Asthma represents a
risk factor for several maternal and fetal complica-
tions, such as asthma exacerbations, use of steroids,
hospitalizations due to asthma attacks, preeclampsia,
gestational hypertension, preterm delivery, cesarean
delivery, low birth weight, intrauterine growth restric-
tion, and fetal death [2-7], posing a need for careful
decision making and optimal training of physicians
treating these patients. Adequate management of
asthma and maintenance of optimal asthma control
during pregnancy decrease perinatal risk [8,9].
The effect of asthma on pregnancy
Pregnancy is characterized by immunological toler-
ance (physiological immunosuppression) that blunts
maternal immune response against paternal antigens
expressed by the fetus [10]. Physiological pregnancy
has been described as a Th2-dominated state, and
current studies show that proliferating regulatory T
cells (Tregs) may have a key role in the maintenance
of peripheral tolerance to paternal antigens during
pregnancy [11]. Treg cells, however, exert an
inhibitory effect on natural killer lymphocytes
responsible for protection against viruses [12] that
may contribute to increased susceptibility to viral
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3 infections (e.g. influenza), as observed with H1N1
influenza in pregnant women [13]. Diminished
numbers of Treg cells in pregnancy were associated
with immunological rejection of the fetus as well as
preeclampsia and low fetal birth weight [14]. 
Asthma is traditionally considered as an allergic T
helper cell 2 (Th2) type inflammation that leads to
bronchial hyperresponsiveness, airway obstruction
and – in some cases – tissue remodeling [15].
Immunological changes in asthmatic pregnancy are
not well established. In a recent study we found
signs of pregnancy-induced attenuation of allergic
responses. Activated pools within CD4 and CD8 T
cells were larger, and the number of natural killer T
(NKT) cells was increased both in non-pregnant
asthmatic and in healthy pregnant subjects (com-
pared to non-pregnant healthy controls), but in
(mostly well controlled) pregnant asthmatics no fur-
ther lymphocyte activation was observed suggesting
that the immunosuppressive effect of uncomplicat-
ed pregnancy may blunt the lymphocyte activation
which characterizes asthma [16]. On the other
hand, in our earlier study a significant amount of
interferon (IFN)-γ producing cells was detected in
peripheral blood obtained from not well controlled
asthmatic pregnant women and a significant nega-
tive correlation was revealed between the number
of IFN-γ positive T-cells and birth weight of new-
borns, pointing at fetal growth retardation related to
active, asthma-associated maternal immune reac-
tions [17]. In addition, considering another inflam-
matory marker, heat shock protein (Hsp)-70, higher
circulating levels were detected in pregnant asth-
matic women than in healthy pregnant women.
Fetal birth weight is lower in pregnancies compli-
cated with asthma, showing a relationship between
asthmatic immune responses and altered fetal
growth [18]. Supporting the possible adverse effect
of asthmatic inflammation on pregnancy, in a recent
database cohort of 13,100 pregnant asthmatics, a
35% increased risk of perinatal mortality was
observed in the pregnancies of women with asthma
[4]. Major factors contributing to this increased
perinatal mortality might be maternal obesity and
smoking, as well as uncontrolled asthma [5].
Another recent study of pregnant women with
physician-diagnosed asthma evaluated their asthma
control repeatedly during pregnancy based on
symptom frequency and interference with daily
activities and sleep, and reported hospitalizations
and unscheduled clinic visits for asthma exacerba-
tions. According to their results, the incidence of
preterm delivery is higher among patients with
inadequate asthma symptom control during the first
part of pregnancy compared to patients with ade-
quate asthma control, and patients who are hospi-
talized for asthma during pregnancy have a higher
incidence of preterm delivery compared to asthmat-
ic women without a history of hospitalization. Thus
there may be a risk for preterm delivery posed by
poorly controlled maternal asthma [8]. Maternal
asthma is also known as a risk factor for the devel-
opment of asthma in children [19].
Influence of pregnancy on the course of asthma
Pregnancy has also an effect on the course of asthma.
Asthma improves during pregnancy in about one-
third, remains the same in another one-third, and
worsens in one-third of pregnant women. More
severe asthma before pregnancy represents a higher
risk of worsening during pregnancy and there is a
concordance between the courses of asthma during
subsequent pregnancies [20]. Asthma-specific quali-
ty of life in early pregnancy is related to subsequent
asthma morbidity during pregnancy [21]. 
Severity of asthma symptoms during pregnancy may
also be influenced by fetal gender. Worsened asthma
symptoms [22] and higher incidence of intrauterine
growth retardation [23] were observed in pregnant
asthmatics with female fetuses. On the other hand,
obesity was also associated with an increased risk of
asthma exacerbations during pregnancy [3]. In addi-
tion, maternal obesity without asthma influences also
pregnancy negatively by increasing the risk for
adverse perinatal outcomes (preeclampsia, gestation-
al diabetes, intrauterine fetal retardation and fetal
death) [24]. However, immunological mechanisms
underlying alteration of the course of asthma during
pregnancy or predicting biomarkers of worsening are
largely unknown.
Management of asthma during pregnancy
Diagnosis and monitoring
Due to the bilateral interactions of asthma and preg-
nancy and alterations of asthma severity during preg-
nancy, establishing optimal asthma management dur-
ing gestation often represents a special challenge for
the attending physician. The diagnosis of asthma is
usually known already before pregnancy. However, if
first symptoms occur during gestation, reduced
forced expiratory volume in one second (FEV1) or
ratio of FEV1 to forced vital capacity (FVC), together
with a 12% or greater improvement in FEV1 after
inhalation of rapid acting beta-agonist, confirm the
diagnosis of asthma. Testing bronchial hyperre-
sponiveness is contraindicated during pregnancy
(because of the lack of safety data); thus women with
a clinical picture of new-onset asthma without spiro-
metric confirmation of the diagnosis should be treat-
ed for asthma during pregnancy [25]. Skin prick tests
are not recommended during pregnancy (risk of sys-
temic reactions), but specific IgE antibodies to sus-
pected allergens may be evaluated [25]. 
Assessment of asthma control level in pregnant asth-
matics is similar to the method applied in non-preg-
nant patients [7]. 
Fractioned concentration of nitric oxide present in
exhaled breath (FENO) has been evaluated as a simple
and non-invasive tool for assessing airway inflamma-
tion in asthma [26]. Our recent study provided data
supporting high reproducibility of FENO measurement
in pregnant subjects. According to the results preg-
nancy itself does not alter FENO levels either in
healthy or in asthmatic patients and FENO levels of
pregnant asthmatic patients correlate with the level
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costeroid therapy based on either FENO measure-
ments or current guidelines showed lower daily dose
of inhaled corticosteroid in the FENO group [28].
Since reaching asthma control by using the lowest
possible required dose is critical in pregnant asthmat-
ics, exhaled NO measurement may have importance
in this patient group. 
Treatment
Asthmatic pregnant patients should be educated
about their disease and its treatment (Table I), as
strongly recommended in the GINA guidelines [7].
Smoking cessation is necessary for asthmatic preg-
nant women, due to known adverse effects of smok-
ing on mother’s disease as well as the known higher
risk for neonatal asthma in asthmatic pregnant
women who smoke [29]. According to data on
adverse effects of asthma medications in pregnancy,
most of the findings are reassuring [25]. Many obser-
vational studies have shown no increased perinatal
risks associated with the use of currently available
inhaled beta-agonists and corticosteroids [30-33].
The use of bronchodilators during pregnancy was
associated with an increased risk of gastroschisis
among infants in one study [34]. Higher risk of car-
diac defects was also observed in newborns of asth-
matic pregnants in one study [35]; however, asthma
exacerbation itself during pregnancy may increase
the risk of congenital malformations [36]. 
Generally, according to currently available safety
data albuterol is the reliever medication of prefer-
ence. Considering inhaled corticosteroids, budes-
onide is the preferred choice due to reassuring data
in human pregnancies [32]. Among the long-acting
inhaled beta-agonists, both formoterol and salme-
terol may be used as add-on therapy in pregnant
patients if warranted by symptoms occurring despite
regularly used inhaled corticosteroid therapy.
Leukotriene-receptor antagonists montelukast and
zafirlukast seemed also to be safe during gestation,
but the available human data are scarce [9]. In one
recent study enrolling 180 asthmatic pregnant
women taking montelukast, no increase in the rate of
major congenital malformations was observed [37].
Pregnant patients with well-controlled asthma
should continue taking their medications. Although
in non pregnant and permanently well-controlled
asthmatics the guidelines recommend consideration
of a step down in therapy [7], in pregnant well-con-
trolled patients the maintenance of controller treat-
ment may be decided in order to reduce the risk of
control loss. Therapy should be increased by one step
in patients with asthma that is not well controlled
(Table II). A two-step increase, a course of oral corti-
costeroids, or both should be recommended for
women with asthma that is very poorly controlled
(Table II) [25]. 
Monthly asthma control assessment is recommended
for women who require controller therapy during
pregnancy. Optimal obstetrical care of not well con-
trolled asthmatic pregnant patients means more fre-
quent ultrasonographic examinations (to monitor
fetal growth, which can be affected by uncontrolled
asthma) and assessment of fetal well-being (nonstress
TABLE I: MAIN PATIENT EDUCATIONAL TOPICS FOR 
ASTHMATIC PREGNANT PATIENTS  
Main patient Description
educational topics
General information Basic information about asthma
and its relationship to pregnancy
Facts regarding mother 
and fetus safety
Use of inhaler devices Demonstration of correct use 
of devices prescribed 
to the patient
Adherence to treatment Necessity of regular visits 
and proper controller medication 
during pregnancy complicated 
with asthma
Environmental control Avoidance of known allergens 
measures to reduce exposure and smoking
to allergens and irritants
Self-treatment action plan Written schedule for maintenance 
therapy and doses of rescue 
medication for increased 
symptoms; education about signs 
of asthma exacerbation and urgent
or emergency help providers
TABLE II: STEPS OF ASTHMA MAINTENANCE THERAPY DURING PREGNANCY   
Step Preferred controller medication Alternative controller medication
1 none -
2 Low-dose inhaled corticosteroid LTRA, cromolyn, theophylline
3 Medium-dose inhaled corticosteroid Low-dose inhaled corticosteroid + LABA or LTRA 
or theophylline
4 Medium-dose inhaled corticosteroid + LABA Low-dose inhaled corticosteroid + LTRA or theophylline
5 High-dose inhaled corticosteroid + LABA -
6 High-dose inhaled corticosteroid + LABA 
+ oral corticosteroid -
Definition of abbreviations: LTRA, leukotriene-receptor antagonist; LABA, long-acting beta-agonist.






























3 testing from the 32nd gestational week). During labor
and delivery the use of asthma medications should
be continued. Women who have received systemic
corticosteroids during pregnancy are recommended
to receive intravenous corticosteroids during labor
and for 24 hours after delivery [25].
In conclusion, asthma is probably one of the most
common chronic diseases complicating pregnancy
and influencing its outcome. Generally, although
uncontrolled asthma may increase the risk of adverse
perinatal outcomes, women with well-controlled,
adequately treated disease during pregnancy do not
develop maternal or fetal complications. Good and
frequent communication between obstetrics, pulmo-
nologists, allergist and general practitioners is a vital
necessity of asthma treatment during pregnancy. 
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